The UniCAR platform was designed to control the universal chimeric antigen receptor (CAR) T-effector cell through a rapidly switchable on/off capability. In combination with the ability to target specific tumor antigens by redirecting and activating UniCAR-T cells through soluble adapters (targeting modules), the platform offers a high degree of flexibility. The targeting modules provide antigen-specificity to activate UniCAR gene-modified T cells.

The phase IA study includes patients with late-stage PSMA-positive relapsed/refractory solid tumors such as castrate resistant prostate cancer, non-small cell lung cancer, or triple-negative breast cancer.

The study will evaluate the safety and potential efficacy of the combined application of a single dose of UniCAR-T and continuous infusion of PSMA-specific targeting modules.

Umoja Biopharma to develop in vivo immunotherapy platform
Umoja Biopharma has completed $53 million in series A financing to support development of its in vivo immunotherapy platform.

Caribou inks deal with MSK to make allogeneic therapies
Memorial Sloan Kettering Cancer Center (MSK) has agreed to exclusively license its antibody fragments to CRISPR genome editing firm Caribou Biosciences...

Poseida CAR T clinical trial hold lifted
The U.S. Food and Drug Administration has lifted a clinical trial hold on Poseida Therapeutics' phase I study of P-PSMA-101, an autologous chimeric antigen...

Gracell secures funding to advance CAR T therapies
Gracell Biotechnologies has secured $100 million in series C funding to expand its chimeric antigen receptor (CAR) T-cell therapies.

Precigen nabs FDA nod for manufacturing UltraCAR-T therapies
Precigen has been granted clearance by the U.S. Food and Drug Administration (FDA) for its UltraPorator system. The system also had a successful technology...